Hester Biosciences LtdQ1 FY23Pharmaceuticals & Biotechnology

Hester Biosciences Ltd

Q1 FY23 Earnings Call Analysis

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

Order

Capex

0 of 5 growth signals are positive — mixed outlook.

Revenue guidance

Category 3

→Target to achieve Rs.600 Crores revenue in approximately 3 years through current capacity in India, Nepal, and Africa (Rajiv Gandhi).
→African subsidiary in Tanzania expected to ramp up to $25 million sales in 4-5 years, leveraging existing capacity (Rajiv Gandhi).
→Poultry vaccine sales showing recovery, following an industry downturn; expectation of industry improvement from current low levels (Rajiv Gandhi).
→Health products growing rapidly (60% increase quarter-on-quarter) though currently smaller base; focus on increasing cycles of health products to drive EBITDA growth (Rajiv Gandhi).
→Pet care business is a sunrise industry in India, growing at around 20% YoY, with significant future potential due to increase in pet ownership (Rajiv Gandhi).
→Immunization programs like Government of India’s PPR program (Rs.40 Crores tender) expected to boost sales (Priya Gandhi).
→Overall optimistic about revenue growth higher than last year with improved bottom lines.

Category 3

→Hester Biosciences aims to restore and improve margins to previous levels despite current challenges, combining both vaccine and health product sales.
→Management is optimistic about revenue growth, expecting a higher growth rate this year compared to last year.
→The poultry division is anticipated to recover from its current low phase, showing improvement quarter-on-quarter.
→Health products and pet care business are viewed as growth drivers, with the pet segment growing ~20% YoY, faster than poultry or animal healthcare.
→New immunization programs like the Government's PPR vaccination tender (Rs.40 Cr order) will boost sales in the coming year.
→African and Nepal subsidiaries plan gradual capacity ramp-ups, targeting $25M revenue in Africa over 4-5 years.
→Overall, the company expects sales to increase, profit margins to improve, and sustainable growth over the next 3 years with a target of Rs.600 Cr revenue expansion.

Get access to all 5 sections — revenue, margin, fundraise, orderbook, and capex — for Hester Biosciences Ltd and 1,400+ other companies.

→Currently, Hester Biosciences has no plans for taking additional debt or loans.
→The company is at its highest borrowing level, but the debt is expected to reduce over time.
→No additional capital expenditure (capex) is required for ongoing projects at present.
→Approximately Rs.10-12 Crores payable for existing capital creditors related to current projects.
→Any new capital expenditure or fund raising would be a different situation, but currently, they are fully covered for expansions with invested capital.
→Grants related to specific projects may continue to come but not considered as regular fundraising.
→Overall, no planned fundraising through debt or equity in the near term based on management comments.

→Hester Biosciences currently has orders in hand worth around Rs.15 Crores in Nepal.
→Various tenders are in process in Nepal, indicating ongoing order activity.
→There is a mention of unexecuted orders for the PPR vaccine, due to a shift in government focus to lumpy skin disease, expected to be fulfilled soon.
→Immunization programs impact quarterly sales based on the timing of government orders, causing some variability in order execution.
→The company is also targeting the domestic market alongside tender-based business, with increasing revenues expected from this segment.

→No significant additional capex is currently planned for ongoing projects; only Rs.10-12 Crores payable for existing capital creditors.
→Fill-finish facility under construction expected to commission within ~60 days; this will double vaccine capacity in India.
→BSL-III laboratory (COVID bulk antigen manufacturing) facility being repurposed post-COVID.
→Capital already invested covers current expansion potentials: Rs.50 Crores in Nepal, $25-30 million (~Rs.200 Crores) in Africa, and an additional Rs.200 Crores capacity potential in India.
→Any new capital investment would be situational and unlikely at this moment.
→Grants related to specific projects (like COVID) may continue but are project-specific, not recurring.
→Overall, the company is capital-ready to support growth without needing substantial new capex immediately.

How does Hester Biosciences Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Hester Biosciences Ltd

Rev 3Mar 3

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Hester Biosciences Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.